Short Sellers Run for Cover From Major Biotechs
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
Mylan is expected to release its second-quarter financial results after the markets close on Tuesday.
The analysts at Stifel have noted three biotech companies that not only have data that could prove to be huge, but also have stocks that have been absolutely hammered over the past year.
Valeant Pharmaceuticals International appears to have a turnaround underway, after the company reported its second-quarter financial results before the markets opened on Tuesday.
If the Zika virus should spread beyond its currently known location near Miami, it could threaten some of Florida's largest tourist attractions, like DisneyWorld and Universal Orlando.
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
In Miami, spraying for Zika is in full swing. However, infection rates continue to rise, and the virus has begun to spread among other states.
There have been several developments since 24/7 Wall St. posted its Theranos Death Watch Continues story.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
A new report from Wedbush focuses on upcoming catalysts for biotech stocks in the firm's coverage universe. These four have monster potential upside to the posted price targets.
According to one analyst, Advaxis shares could still easily more than double, even after news broke that biotech giant Amgen will become its partner.